A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted ...

Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint and provided a ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...